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Abstract
Background: Kaposi’s sarcoma-associated herpesvirus (KSHV) is causally linked to several acquired
immunodeficiency syndrome-related malignancies, including Kaposi’s sarcoma (KS), primary effusion lymphoma
(PEL) and a subset of multicentric Castleman’s disease. Regulation of viral lytic replication is critical to the initiation
and progression of KS. Recently, we reported that herpes simplex virus type 1 (HSV-1) was an important cofactor
that activated lytic cycle replication of KSHV. Here, we further investigated the possible signal pathways involved in
HSV-1-induced reactivation of KSHV.
Results: By transfecting a series of dominant negative mutants and protein expressing constructs and using
pharmacologic inhibitors, we found that either Janus kinase 1 (JAK1)/signal transducer and activator of transcription
3 (STAT3) or JAK1/STAT6 signaling failed to regulate HSV-1-induced KSHV replication. However, HSV-1 infection of
BCBL-1 cells activated phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB, also called AKT) pathway and
inactivated phosphatase and tensin homologue deleted on chromosome ten (PTEN) and glycogen synthase
kinase-3b (GSK-3b). PTEN/PI3K/AKT/GSK-3b pathway was found to be involved in HSV-1-induced KSHV reactivation.
Additionally, extracellular signal-regulated protein kinase (ERK) mitogen-activated protein kinase (MAPK) pathway
also partially contributed to HSV-1-induced KSHV replication.
Conclusions: HSV-1 infection stimulated PI3K/AKT and ERK MAPK signaling pathways that in turn contributed to
KSHV reactivation, which provided further insights into the molecular mechanism controlling KSHV lytic replication,
particularly in the context of HSV-1 and KSHV co-infection.
1. Background
Kaposi’s sarcoma (KS) is a multifocal angioproliferative
disease that often occurs in human immunodeficiency
virus (HIV)-infected patients [1]. Now the accepted etio-
logical agent of KS is KS-associated herpesvirus
(KSHV)/human herpesvirus 8 (HHV-8) [2]. KSHV is
also associated with another lymphoproliferative disor-
ders: primary effusion lymphoma (PEL, also termed
body cavity-based lymphoma, or BCBL) and multicentric
Castleman’s disease (MCD) [3]. All herpesviruses,
including KSHV, display two patterns of infection: latent
and lytic phases [4]. During latency, only a restricted set
of viral genes is expressed. Upon induction of lytic
infection, viral replication and transcription programs
become fully activated, and new virions are packaged
and released from the cells. Regulation of viral infection
cycle is critical to the initiation and progression of KS.
However, KSHV infection appears to be necessary but
not sufficient for the development of KS without the
involvement of other cofactors to reactivate KSHV lytic
replication.
Previously, we demonstrated that both interleukin-4
(IL-4)/signal transducer and activator of transcription 6
(STAT6) and IL-6/Janus kinase 2 (JAK2)/STAT3 signal
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protein (Tat)-induced KSHV replication [5]. Recently,
we have also shown that herpes simplex virus type 1
(HSV-1) was another important cofactor that reactivated
the lytic cycle replication of KSHV, and the production
of IL-10 and IL-4 from HSV-1-infected BCBL-1 cells
partially contributed to KSHV replication [6]. These
facts led us to hypothesize that HSV-1 might reactivate
KSHV lytic cycle replication by modulating multiple sig-
nal pathways of BCBL-1 cells on the basis of changing
cellular cytokines protein expression profile [6].
To verify this hypothesis, in this study, we focused on
the major pathways activated by IL-10/IL-10 receptor
(R) and IL-4/IL-4R to evaluate their functions in HSV-
1-induced KSHV lytic cycle replication. By transfecting
a series of dominant negative mutants and protein
expressing constructs and using pharmacologic inhibi-
tors, we found that either IL-10/JAK1/STAT3 or IL-4/
JAK1/STAT6 signaling was not involved in HSV-1-
induced KSHV replication. However, activation of both
phosphatidylinositol 3-kinase (PI3K)/protein kinase B
(PKB, also called AKT) and extracellular signal-regulated
protein kinase (ERK) mitogen-activated protein kinase
(MAPK) signal pathways contributed to HSV-1-induced
KSHV replication. These novel findings are believed to
be the first report on the mechanisms of KSHV activa-
tion by HSV-1 and shed light on the pathogenesis of
KSHV-induced malignancies.
2. Methods
2.1. Cell culture and virus infection
BCBL-1 cells (KSHV-positive and EBV-negative PEL cell
lines) were obtained through acquired immunodefi-
ciency syndrome (AIDS) Research and Reference
Reagent Program, National Institutes of Health. Vero
cells (African green monkey kidney fibroblasts) were
obtained from American Type Culture Collection
(ATCC). BCBL-1 and Vero cells were maintained in
RPMI-1640 and Dulbecco’s modified Eagle’sm e d i u m
(DMEM) respectively, both of which contained 10% fetal
bovine serum (FBS), 2 mmol/l L-glutamine, 100 U/ml
penicillin, and 100 μg/ml streptomycin at 37°C in a
humidified, 5% CO2 atmosphere. HSV-1 (McKrae strain)
was propagated and viral titers were determined in Vero
cells as described previously [6]. The supernatant from
normal Vero cells culture was used as a control (Mock).
Before infection or transfection, BCBL-1 cells were incu-
bated in serum-free RPMI-1640 medium for a maxi-
mum inducibility of KSHV replication [7].
2.2. Antibodies and reagents
Anti-phospho-STAT3 (Tyr705) rabbit monoclonal
antibody (mAb), anti-phospho-PI3K p85 (Tyr458)/p55
(Tyr199) rabbit polyclonal antibody (pAb), anti-
phospho-AKT (Ser473) mouse mAb, anti-phospho-
GSK-3b (Ser9, GSK: glycogen synthase kinase) rabbit
pAb, anti-phospho-c-Raf (Ser338) rabbit pAb, anti-
phospho-MEK1/2 (Ser217/221, MEK: MAPK-ERK
kinase) rabbit pAb, anti-phospho-ERK1/2 (Thr202/
Tyr204) rabbit mAb, anti-STAT3 rabbit pAb, anti-
PI3K p85 rabbit pAb, anti-GSK-3b rabbit mAb, anti-c-
Raf rabbit pAb, anti-MEK1/2 rabbit pAb, anti-Flag M2
mouse mAb, anti-hemagglutinin (HA) rabbit mAb and
LY294002 (PI3K inhibitor) were purchased from Cell
Signaling Technologies (Beverly, MA, USA). Anti-
PTEN (PTEN: phosphatase and tensin homologue
deleted on chromosome ten) mouse mAb, anti-b-actin
mouse mAb, anti-a-Tubulin mouse mAb, anti-GAPDH
mouse mAb and horseradish peroxidase (HRP)-conju-
gated goat anti-mouse/rabbit IgG were obtained from
Santa Cruz Biotechnologies (Santa Cruz, CA, USA).
Anti-AKT rabbit pAb were obtained from BioVision
(Mountain view, CA, USA). Anti-ERK1/2 rabbit pAb
were obtained from Shanghai Kangchen Biotechnolo-
gies (Shanghai, China). Piceatannol (JAK1 inhibitor)
was purchased from BIOMOL Research Laboratories
Inc. (Plymouth Meeting, PA, USA). Both anti-phospho-
STAT6 (Tyr641) mouse mAb and Peptide II (ERK
inhibitor) were obtained from Calbiochem (Darmstadt,
Germany). Anti-STAT6 rabbit pAb was purchased
from Bethyl Laboratories Inc. (Montgomery, TX, USA).
Anti-KSHV ORF59 mAb and viral IL-6 (vIL-6) rabbit
pAb were obtained from Advanced Biotechnologies
Inc. (Columbia, MD, USA). Anti-KSHV Rta (replica-
tion and transcription activator) antibody was gener-
ated by immunization of rabbits with ORF50 peptide
(amino acids 667-691) [8].
2.3. Western blot analysis
After infection, cells were harvested and lysed in RIPA
buffer containing protease and phosphatase inhibitors.
60-80 μg of proteins were loaded onto sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred to polyvinylidene fluoride (PVDF)
membrane. The membrane was incubated with diluted
primary Abs for overnight at 4°C, and then incubated
with HRP-conjugated species-specific second Abs for 1
h at 37°C. Proteins were visualized by enhanced chemi-
luminescence (ECL) reagents (Cell Signaling Technolo-
gies) according to the manufacture’s instructions.
2.4. RNA isolation and real-time quantitative PCR (RT-
qPCR)
Total RNA was isolated from cells by using Trizol
reagent (Invitrogen, Carlsbad, CA). RT-qPCR was per-
formed in a GeneAmp 7300 sequence detection
machine (Applied Biosystems, Foster City, CA) as
described previously [9]. The sequences of KSHV
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viously [9].
2.5. Plasmids and transfection
The dominant negative STAT3 construct (pMSCV-
STAT3 dominant negative-GFP, abbreviated pST3-DN)
was kindly provided by D. Link (Washington University
School of Medicine, MO, USA) [10]. The dominant
negative STAT6 construct (pDsRed1-N1-STAT6 domi-
nant negative-RFP, abbreviated pST6-DN), containing
amino acids 1-661 of STAT6, was a kind gift of K.
Zhang (UCLA School of Medicine, CA, USA) [11]. The
dominant negative construct of PI3K (P85siSH2-N,
designated as PI3K-DN in this study), the dominant
negative construct of AKT (SRa-AKT, designated as
AKT-DN), and corresponding control vectors pSG5 and
pSRa were generously provided by B-H Jiang (Nanjing
Medical University, Nanjing, China) [12]. The dominant
negative MEK1/2 construct (MEK-DN) was presented as
a gift by G. Chen (Medical College of Wisconsin, WI,
USA). The protein expressing plasmid of GSK-3b (GSK-
3b- S 9 A ,t h e r ew a sat a go fH A )w a sp u r c h a s e df r o m
Addgene (http://www.addgene.org). The PTEN cDNA
plasmid (there was a tag of Flag) was constructed in our
lab. BCBL-1 cells were electroporated at 250 V and 960
μF using a Gene Pulser (Bio-Rad Laboratories, Hercules,
CA) as described elsewhere [13].
2.6. Detection of the release of KSHV progeny virions
After BCBL-1 cells were infected with HSV-1 for 48 h,
supernatant from cell cultures was harvested and filtered
through a 0.45-μm-pore-size filter. The filtered superna-
tant was centrifugated for 30 min at a speed of 15 000
rpm at 4°C and the precipitation contained KSHV pro-
geny virions. The virions were resuspended in PBS and
viral DNA was extracted using the high pure viral
nucleic acid kit (Roche, Germany) as per the manufac-
turer’s instructions. Purified viral DNA was used for
real-time DNA-PCR analysis. The KSHV ORF26 gene
cloned in the pcDNA3.1 (abbreviated pcDNA, Invitro-
gen) was used to generate the standard curve.
2.7. Immunofluorescence assay (IFA)
IFA was performed as described elsewhere [14]. Briefly,
after HSV-1 infection, BCBL-1 cells were washed and
smeared on chamber slides. Slides were incubated with
a 1:100 dilution of anti-KSHV ORF59 mouse mAb.
Alexa Fluor 568 (Invitrogen)-conjugated goat anti-
mouse antibody (1:200 dilution) was used as a secondary
antibody for detection. The cells were counterstained
with 4’,’-diamidino-2-phenylindole. Images were
observed and recorded with a Zeiss Axiovert 200 M epi-
fluorescence microscope (CarlZ e i s s ,I n c . ) .P h o t o g r a p h s
of at least 10 unique fields were taken of every slide,
and the number of positive and negative cells was
counted separately by three individuals, including one
who was blinded to the results to calculate the percen-
tage of positive cells.
3. Results
3.1. Inhibition of JAK1/STAT3 and JAK1/STAT6 signal
pathways does not affect HSV-1-induced KSHV lytic cycle
replication
We have previously demonstrated that the production of
IL-10 and IL-4 from HSV-1-infected BCBL-1 cells par-
tially contributed to HSV-1-induced KSHV replication
[6]. Commonly, IL-10 exerts its function via JAK1,
TYK2/STAT3 signal pathway, and IL-4 through JAK1,
JAK3/STAT6 pathway [15-17 ] .T od e t e r m i n ew h e t h e r
these signal pathways were altered in HSV-1-infected
BCBL-1 cells, Western blot analysis was performed. As
shown in Figure 1A, HSV-1 infection of BCBL-1 cells
did not display any effect on phosphorylation of STAT3
or STAT6 at 3, 6, 12, and 24 h when compared to
Mock-infected groups. Similar results were also
observed when BCBL-1 cells were infected with HSV-1
or Mock at 15, 30, 45, and 60 min (data not shown). To
confirm these results, BCBL-1 cells were transfected
with STAT3-DN or STAT6-DN construct followed by
HSV-1 infection. RT-qPCR demonstrated that transfec-
tion of either STAT3-DN or STAT6-DN did not affect
KSHV ORF26 mRNA transcripts induced by HSV-1 in
BCBL-1 cells (Figure 1B and 1C). To further extend
above results, piceatannol, a JAK1 tyrosine kinase-speci-
fic inhibitor, was added to BCBL-1 cells culture before
HSV-1 infection. The results from RT-qPCR indicated
that inhibition of JAK1 did not influence KSHV replica-
tion by HSV-1 (data not shown). These data collectively
suggest that either IL-10/JAK1/STAT3 or IL-4/JAK1/
STAT6 signal pathway is not involved in HSV-1-
induced KSHV replication.
3.2. Suppression of PI3K/AKT signal pathway inhibits HSV-
1-induced KSHV replication
Besides signal pathways from JAK1/STAT3 by IL-10 and
JAK1/STAT6 by IL-4, both IL-10 and IL-4 can also
induce activation of PI3K/AKT pathway [18-20]. To
examine whether PI3K/AKT signaling was activated in
HSV-1-infected BCBL-1 cells, Western blot analysis was
carried out. It was demonstrated that phosphorylated
PI3K and AKT were markedly increased at 12, 24, and
48 h in HSV-1-infected BCBL-1 cells when compared
with Mock-infected BCBL-1 cells (Figure 2).
To examine whether PI3K/AKT pathway was involved
in KSHV lytic cycle replication by HSV-1, PI3K-specific
inhibitor LY294002 was first used. RT-qPCR demon-
strated that ORF26 mRNA in HSV-1-infected BCBL-1
cells pretreated with LY294002 was decreased 3.27-fold
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infection of HSV-1, respectively, compared to HSV-1-
infected BCBL-1 cells pretreated with DMSO (Figure
3A). To confirm this result, Western blot analysis was
performed. We found that pretreatment of LY294002
inactivated the downstream kinase AKT and reduced
the expression of KSHV vIL-6 proteins (Figure 3B).
Next, PI3K-DN, the dominant negative form of PI3K,
was transfected to BCBL-1 cells followed by HSV-1
infection. As shown in Figure 3C, control plasmid pSG5
alone did not affect KSHV activation by HSV-1, but
transfection of PI3K-DN decreased HSV-1-induced
KSHV Rta and vIL-6 expression. Finally, AKT-DN, the
dominant negative form of AKT, was transfected to
BCBL-1 cells followed by HSV-1 infection. Western blot
analysis demonstrated that transfection of control plas-
mid pSRa alone did not influence KSHV replication,
but transfection of AKT-DN down-regulated the
proteins expression of KSHV Rta and vIL-6 (Figure 4A).
The results from IFA also indicated that transfection of
AKT-DN significantly decreased HSV-1-induced KSHV
ORF59 proteins expression (Figure 4B and 4C). These
data suggest that activation of PI3K/AKT pathway
involves in HSV-1-induced KSHV replication.
3.3. Both overexpression of PTEN and activation of GSK-
3b pathway also inhibit HSV-1-induced KSHV reactivation
From Figure 2, we observed that expression of PTEN
(negative regulator of PI3K/AKT pathway) was low in
HSV-1-infected BCBL-1 cells, therefore, we asked
whether overexpression of PTEN could influence HSV-
1-induced KSHV replication. To address this issue, the
PTEN cDNA construct was transfected to the cells.
Western blot analysis demonstrated that overexpression
of PTEN not only decreased phosphorylated AKT and
GSK-3b (data not shown), but also reduced HSV-1-
B
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Figure 1 Either JAK1/STAT3 or JAK1/STAT6 signal pathway does not mediate HSV-1-induced KSHV replication. (A) Western blot analysis
for phosphorylation of STAT3 and STAT6. BCBL-1 cells were infected with Mock (M) or HSV-1 (H) for 3, 6, 12, and 24 h. Cells were collected and
cell lysates were subjected to SDS-PAGE, transferred to membrane, and then immunoblotted with the indicated antibodies. (B) RT-qPCR was
used to detect relative quantities of ORF26 mRNA in STAT3-DN (pST3-DN) or control vector transfected and HSV-1 infected BCBL-1 cells as
indicated. ** p < 0.01 and *** p < 0.001 for Student’s t-test versus Mock + pMSCV group; n.s., not significant for Student’s t-test versus HSV-1 +
pMSCV group. (C) RT-qPCR was used to detect relative quantities of ORF26 mRNA in STAT6-DN (pST6-DN) or control vector transfected and HSV-
1 infected BCBL-1 cells as indicated. ** p < 0.01 and *** p < 0.001 for Student’s t-test versus Mock + pRed group; n.s., not significant for
Student’s t-test versus HSV-1 + pRed group.
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ure 5A). To further determine whether overexpression
of PTEN could reduce the release of KSHV progeny vir-
ions induced by HSV-1, experiments were designed to
detect the copy number of KSHV progeny virions. The
results of real-time DNA-PCR demonstrated that the
copy number of KSHV virions in the supernatant from
PTEN-transfected and HSV-1 infected BCBL-1 cells was
significantly decreased when compared to those from
pcDNA-transfected and HSV-1 infected BCBL-1 cells
(Figure 5B).
Because HSV-1 infection of BCBL-1 cells increased
phosphorylated GSK-3b (Figure 2) and transfection of
PI3K-DN decreased HSV-1-induced phosphorylation of
GSK-3b (Figure 3C), we reasoned that inactivated GSK-
3b might promote HSV-1-induced KSHV replication.
To test this hypothesis, the GSK-3b mutant plasmid
GSK-3b-S9A, which exhibits constitutively active GSK-
3b, was transfected to BCBL-1 cells. As expected, the
expression of KSHV Rta and vIL-6 proteins in GSK-3b-
S9A-transfected and HSV-1 infected BCBL-1 cells was
markedly reduced compared to pcDNA-transfected and
HSV-1 infected BCBL-1 cells (Figure 5C).
Taken together, these data suggest that PTEN/PI3K/
AKT/GSK-3b pathway may play an important role in
HSV-1-induced KSHV reactivation.
3.4. ERK MAPK pathway partially contributes to HSV-1-
induced KSHV replication
Because IL-4 can also induce activation of ERK MAPK
pathway [21,22], we reasoned that ERK MAPK signaling
might be activated in HSV-1-infected BCBL-1 cells. To
this end, Western blot analysis was performed to detect
activation of ERK MAPK pathway. We found that HSV-
1 infection of BCBL-1 cells increased phosphorylated c-
Raf, MEK1/2 and ERK1/2 at 12, 24, and 48 h when
compared to Mock-infected group (Figure 6).
To evaluate the role of ERK MAPK pathway in KSHV
replication, MEK-DN, the dominant negative form of
MEK1/2, was first used. Western blot analysis demon-
strated that control plasmid pcDNA alone did not affect
KSHV reactivation by HSV-1, but transfection of MEK-
DN lowered HSV-1-induced KSHV Rta and vIL-6
expression through the inhibition of phosphorylation of
downstream kinase ERK1/2 (Figure 7A). Next, real-time
DNA-PCR was utilized to quantitatively detect the copy
number of KSHV progeny virions. It was indicated that
t h ec o p yn u m b e ro fK S H Vv i r i o n si nt h es u p e r n a t a n t
from MEK-DN-transfected and HSV-1 infected BCBL-1
cells was significantly decreased compared to the corre-
sponding control (Figure 7B). Further, peptide II, an
ERK-specific inhibitor, was added to BCBL-1 cells cul-
ture before HSV-1 infection. The results from RT-qPCR
indicated that ORF26 mRNA in HSV-1-infected BCBL-1
cells pretreated with peptide II was decreased 2.56-fold
at 12 h, 2.73-fold at 24 h, and 1.78-fold at 48 h, respec-
tively, when compared to HSV-1-infected BCBL-1 cells
pretreated with H2O (Figure 7C). Similarly, the results
from IFA demonstrated that treatment of peptide II of
HSV-1-infected BCBL-1 cells significantly decreased
KSHV ORF59 proteins expression (Figure 7D and 7E).
These observations collectively suggest that ERK
MAPK pathway also contributes to HSV-1-induced
KSHV replication.
4. Discussion
Deregulation of cellular signal pathways is involved in
the infection process and replication of many viruses
and is also likely to contribute to pathogenesis and viral
oncogenesis. Many signal pathways, such as JAK/STAT,
PI3K/AKT, MAPK, protein kinase C (PKC), nuclear fac-
tor kappa B (NF-B) and Notch have been shown to
participate in KSHV infection, replication and angiogen-
esis [5,23-29]. In this study, we did not observe any evi-
dence that JAK1/STAT3 and JAK1/STAT6, which were
the traditional pathways activated by IL-10/IL-10R and
IL-4/IL-4R, were involved in KSHV replication by HSV-
1, but PI3K/AKT and ERK MAPK pathways induced by
IL-10 and IL-4 contributed to this replication.
PI3K/AKT signaling pathway plays an important role
in cell growth and survival. PI3K is a heterodimer
Figure 2 Western blot analysis for phosphorylation of
important molecules of PI3K/AKT pathway. BCBL-1 cells were
infected with Mock (M) or HSV-1 (H) for 12, 24, and 48 h. Cells were
collected and cell lysates were subjected to SDS-PAGE, transferred
to membrane, and then immunoblotted with the indicated
antibodies.
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regulatory subunit p85 [30]. PI3K activation leads to
AKT activation. AKT is a critical regulator of PI3K-
mediated cell survival and AKT phosphorylates and
inactivates several proapoptotic proteins including GSK-
3b [31]. PTEN is a negative regulator of PI3K/AKT
pathway [32]. PTEN counters the effects of PI3K and
inhibits AKT. PTEN is inactivated by phosphorylation,
leading to the activation of AKT. With respect to KSHV
and activation of PI3K/AKT, many studies focused on
viral G protein-coupled receptor (vGPCR) and K1 genes.
PI3K/AKT pathway played an essential role in vGPCR
sarcomagenesis [33,34]. The activation of PI3K/AKT
pathway by K1 promoted cell survival and immortaliza-
tion and might contribute to KSHV-associated tumori-
genesis [35,36]. In this study, we have provided direct
experimental evidence that not only suppression of
PI3K/AKT signal pathway, but also overexpression of
PTEN and activation of GSK-3b inhibited HSV-1-
induced KSHV replication, implying complicated func-
tions of PI3K/AKT pathway not only in viral oncogen-
esis. Interestingly, a report showed that inhibition of
PI3K pathway did not impair induction of KSHV lytic
replication by metabolic end products of Gram-negative
anaerobic bacteria [37]. Another study demonstrated
that inhibition of PI3K/AKT pathway enhanced KSHV
and murine gammaherpesvirus-68 (MHV-68) lytic repli-
cation [38]. We speculated that there were at least three
reasons: (1) different inducers and cell lines may exhibit
different mechanisms and effects, (2) PI3K and AKT
both have a wide range of cellular targets and show
complicated functions dependent on the context, and
(3) we also simultaneously used dominant negative pro-
tein expression plasmids of this pathway, while Peng et
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Figure 3 Inhibition of PI3K suppresses HSV-1-induced reactivation of KSHV. (A) RT-qPCR was used to detect relative quantities of ORF26
mRNA in LY294002 or DMSO control pretreated and HSV-1 infected BCBL-1 cells as indicated. ** p < 0.01 and *** p < 0.001 for Student’s t-test
versus Mock + DMSO group;
## p < 0.01 for Student’s t-test versus HSV-1 + DMSO group. (B) Western blot analysis was used to detect the
expression of KSHV vIL-6 and phosphorylated AKT in LY294002 or DMSO pretreated and HSV-1 infected BCBL-1 cells as indicated. (C) Western
blot analysis was used to detect the expression of KSHV Rta, vIL-6 and phosphorylated GSK-3b in PI3K-DN or control vector transfected and HSV-
1 infected BCBL-1 cells as indicated.
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Figure 4 Inhibition of AKT suppresses HSV-1-induced reactivation of KSHV. (A) Western blot analysis was used to detect the expression of
KSHV Rta and vIL-6 in AKT-DN or control vector transfected and HSV-1 infected BCBL-1 cells as indicated. (B) KSHV lytic proteins ORF59
expression in AKT-DN or control vector transfected and HSV-1 infected BCBL-1 cells was detected by IFA staining with ORF59 mAb. Original
magnifications, × 10. (C) Quantification of results in B. *** P < 0.001 for Student’s t-test versus Mock + pSRa group, whereas **P < 0.01 for
Student’s t-test versus HSV-1 + pSRa group.
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Figure 5 Overexpression of PTEN and activation of GSK-3b inhibit HSV-1-induced KSHV reactivation. (A) Western blot analysis was used
to detect the expression of KSHV Rta, vIL-6 and the level of the transfected PTEN in PTEN or control vector transfected and HSV-1 infected
BCBL-1 cells as indicated. (B) Real-time DNA-PCR was used to detect the copy number of KSHV progeny virions in the supernatant of PTEN or
control vector transfected and HSV-1 infected BCBL-1 cells as indicated. ** p < 0.01 and
## p < 0.01 for Student’s t-test versus Mock + pcDNA
and HSV-1 + pcDNA groups, respectively. (C) Western blot analysis was used to detect the expression of KSHV Rta, vIL-6 and the level of the
transfected GSK-3b-S9A in GSK-3b-S9A or control vector transfected and HSV-1 infected BCBL-1 cells as indicated.
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inhibitors are known to have pleiotropic effects, the use
of dominant negative protein expression plasmids is of
value. In addition, authors of these two studies detected
only the effects of inhibition of PI3K or AKT on the
reactivation of KSHV in PEL cell lines, but the upstream
and downstream effectors were not shown.
MAPK cascades are key signaling pathways involved in
the regulation of cell proliferation, survival and differen-
tiation. It is not surprising that many viruses including
KSHV target MAPK pathways as a means to manipulate
cellular function and to control viral infection and repli-
cation. Studies from Gao’s group demonstrated that
ERK, c-Jun N-terminal kinase (JNK) and p38 multiple
MAPK pathways had general roles in regulating the life
cycle of KSHV by mediating both viral infection and
switch from viral latency to lytic replication [39,40].
Among three major MAPK pathways, ERK MAPK path-
way has particularly been the subject of intense research
in cancer treatment [41]. Because of the fact that KSHV
can cause malignancies, KSHV researchers pay more
attention to ERK MAPK pathway. There were some
Figure 6 Western blot analysis for phosphorylation of
important molecules of ERK MAPK pathway. BCBL-1 cells were
infected with Mock (M) or HSV-1 (H) for 12, 24, and 48 h. Cells were
collected and cell lysates were subjected to SDS-PAGE, transferred
to membrane, and then immunoblotted with the indicated
antibodies.
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Figure 7 ERK MAPK pathway partially contributes to HSV-1-induced KSHV replication. (A) Western blot analysis was used to detect the
expression of KSHV Rta, vIL-6 and phosphorylated ERK in MEK-DN or control vector transfected and HSV-1 infected BCBL-1 cells as indicated. (B)
Real-time DNA-PCR was used to detect the copy number of KSHV progeny virions in the supernatant of MEK-DN or control vector transfected
and HSV-1 infected BCBL-1 cells as indicated. ** p < 0.01 and
## p < 0.01 for Student’s t-test versus Mock + pcDNA and HSV-1 + pcDNA groups,
respectively. (C) RT-qPCR was used to detect relative quantities of ORF26 mRNA in peptide II pretreated, HSV-1 infected BCBL-1 cells as indicated.
*** p < 0.001 for Student’s t-test versus Mock + H2O group;
# p < 0.05 and
## p < 0.01 for Student’s t-test versus HSV-1 + H2O group. (D) KSHV
lytic proteins ORF59 expression in peptide II pretreated, HSV-1 48 h infected BCBL-1 cells was detected by IFA staining with ORF59 mAb. Original
magnifications, × 10. (E) Quantification of results in D. ** P < 0.01 and
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groups, respectively.
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KSHV replication. For instance, Ford et al.d e m o n -
strated that inhibiting B-Raf/MEK/ERK signaling by
using MEK-specific inhibitors or siRNA construct tar-
geting B-Raf restrained 12-O-tetradecanoylphorbol-13-
acetate (TPA)-induced KSHV lytic replication [42].
Cohen et al. also showed an essential role of ERK sig-
naling in TPA-induced reactivation of KSHV by using
MEK-specific inhibitors [43]. Yu et al. revealed that Raf/
MEK/ERK pathway mediated Ras-induced KSHV reacti-
vation and the same pathway also mediated TPA-
induced KSHV reactivation and spontaneous reactiva-
tion in PEL cells, by screening expression of a mamma-
lian cDNA library [44]. A more recent study also
showed that alloferon inhibited lytic reactivation of
KSHV through down-regulation of ERK [45]. Here, we
demonstrated a consistent result that activation of ERK
signaling partially contributed to HSV-1-induced KSHV
replication.
5. Conclusions
In summary, we have showed that not JAK1/STAT3 or
JAK1/STAT6 but PTEN/PI3K/AKT/GSK-3b and ERK
MAPK signal pathways partially contributed to HSV-1-
induced KSHV replication. These findings provided
further insights into the molecular mechanism control-
ling KSHV lytic replication and shed light on the patho-
genesis of KSHV-induced malignancies.
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